INTRODUCTION AND OBJECTIVES: It has previously been shown that tumor-derived TGF-b related potent immunosuppression and lack of tumor killing specificity promote CaP progression. Here we report a new immunotherapeutic approach using adoptive transfer of patient-derived PSMA-specific, TGF-b-insensitive human CD8+ T cells to inhibit solid xenograft CaP.
METHODS: Peripheral blood CD8+ T cells were collected from metastatic castration resistant CaP patient by leukapheresis and cultured in the FDA approved Cell Processing Work Station (CPWS, Panasonic) with CD-3 Biotin/CD28/Anti-Biotin Beads (Bead: Cell 1:2) and IL-2 (100units/ml). We developed a TbRIIDN-TK-IRES-PZ1 chimeric T cell receptor retroviral construct using an anti-PSMA IgTCR(z) gene (PZ1) and a dominant negative TGF-b type II receptor (TbRIIDN) that could induce CD8+ T cells to be PSMA reactive and insensitive to TGF-b. PC-3 cells (PSMA negative; ATCC) or PSMA positive PC-3-PSMA cells (Cleveland Clinic) were used for target cells. Subcutaneous injection of PC-3 and PC-3-PSMA cells (2x105 cells/ each, infected with HSV1-tk-GFP-luciferase reporter) into the left and right flank region respectively in each of 48 immunodeficient RAG-1 mice was performed. One week later, the animals were randomly assigned to one of three adoptive transfer groups (16 mice /each group, 2x106 CD8+ T cells/each mice): Group 1: CD8+ T cells infected with TbRIIDN-TK-IRES-PZ1 (71.1% positive); Group 2: Naive CD8+ T cells; Group 3: No treatment group. Tumor growth was monitored by IVIS luciferase imaging. The animals were provided 2 weekly adoptive transfer treatments and sacrificed after 3 weeks. The size and the weight of the tumor were recorded, and the infiltration of CD8+ T cells and apoptosis was evaluated by immunofluorescence staining and TUNEL.
RESULTS: In Group 1, the average tumor weight and volume was significantly lower in the PC3-PSMA tumor (0.413g and 514.2mm3) compared to the PC3 tumor (2.75 g and 3165.2 mm3); (~3-6Â, P<0.05). There was no difference between the PC3 tumor (2.36g and 2768.5mm3 ) compared to PC3-PSMA tumor (2.45g and 2411.99 mm3) in Group 2 or Group 3. H&E staining showed large amount of nuclear fusion, fragmentation and necrosis were found in PC3-PSMA tumors in Group 1 compared to Group 2 and 3. In Group 1, tumor apoptosis (72.5/1,000 mm2) and CD8+ T cell infiltration (45.5/1,000 mm2 ) in PC3-PSMA tumor parenchyma was significantly higher compared to PC3 tumor (6.7/1,000 mm2 and 3.1/1,000 mm2 respectively). There was no significant apoptosis or CD8+ T cells infiltration observed in either PC3 and PC3-PSMA tumor in Group 2 and Group 3.
CONCLUSIONS: Our approach combines TGF-b insensitive with PSMA selectivity that significantly enhance the specificity and tumor killing ability of patient CD8+ T cells, and simultaneously suppress the tumor derived TGF-binduced immunosuppression. Therefore, this construct may offer a novel therapeutic intervention for both primary CaP treatment as well as for recurrence after prostatectomy. 
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INTRODUCTION AND OBJECTIVES:
We conducted a bioinformatic study querying genes involved in cholesterol homeostasis and prostate cancer (PC) outcomes. We found sterol hydroxylase CYP27A1 is correlated with PC progression and is consistently lower in PC vs. normal tissue. Preclinically, we found CYP27A1 overexpression, which metabolizes cholesterol to 27-hydroxycholesterol (27HC), decreased intracellular cholesterol and inhibited PC cell growth in vitro and in vivo. Likewise, treating PC cells with 27HC reduced intracellular cholesterol and decreased in vitro cell proliferation. This has not been tested in vivo. Cellular cholesterol is predominantly concentrated in plasma membrane micro-domains known as lipid rafts, which localize various membrane receptors and facilitate cellular signaling. Preliminarily, we found 27HC causes lipid raft depletion and disorganization reducing JAK2/STAT3 signaling. We hypothesize 27HC mediates its anti-PC activity by inhibiting STAT3-driven PC.
METHODS: In vitro : Cell proliferation, immunoblots, immunoprecipitation, immunofluorescence (IF), matrigel based prostasphere assays and fluorescence activated cell sorting (FACS) techniques were used. In vivo : DU145 PC cells were injected subQ in mice fed a high fat high cholesterol diet for 6 weeks. After tumors grew to an average of 200mm 3 , mice were randomized on tumor size and serum cholesterol into two groups and injected daily with vehicle (cyclodextrin) or 27HC (40mg/kg) for 40 days.
RESULTS: 27HC reduced active phosphorylated STAT3 (p-STAT3) levels in DU145 PC cells in vitro. 27HC inhibited STAT3 dimerization and reduced nuclear STAT3 levels. Adding exogenous cholesterol rescued p-STAT3 levels. Likewise, upstream of STAT3, phosphorylation of JAK2 was reduced by 27HC. Assessment of lipid rafts by IF and FACS showed a decrease and disorganization of lipid rafts after 27HC treatment. 27HC also reduced the number of PC cellderived prostaspheres, which was rescued by cholesterol addback. Finally, our in vivo study showed that 27HC reduced tumor volume over time in a DU145 xenograft model. CONCLUSIONS: 27HC reduced STAT3 signaling in PC cells by inhibiting STAT3 phosphorylation, dimerization and nuclear localization, likely due to reduced lipid raft JAK/STAT signaling. We also observed that 27HC reduces prostasphere numbers in vitro. These 27HC-mediated effects were rescued by cholesterol addback. Lastly, our in vivo study showed that 27HC treatment slowed tumor growth. These data suggest that 27HC may be a novel treatment for STAT3driven PC. Vol. 197, No. 4S, Supplement, Monday, May 15, 2017 THE JOURNAL OF UROLOGY â e1107
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